JANX FINANCIAL STATEMENTS

Janux Therapeutics Inc — balance sheet, income statement and cash flow trends

JANXJanux Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue21.6 M $+2,522.9%

Gross Profit11.2 M $—

Operating Income-157 M $—

EBITDA-112.4 M $—

Net Income-114.5 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
JANX	2,522.9%	51.6%	-520.3%	-529.7%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
JANX	2,522.9%	51.6%	-520.3%	-529.7%
KURA	5.4%	94.7%	-408.0%	-411.2%
DSGN	-100.0%	—	—	—
ABUS	2,889.9%	100.0%	84.0%	84.0%
LXRX	123.1%	99.1%	-25.0%	-37.5%
PHAT	150.3%	84.9%	-44.4%	-76.8%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity941.5 M $92%
Current Liabilities58.9 M $6%
Long-term Liabilities27.8 M $3%

Key Figures

YoY change

Total Assets1 B $-2.1%

Total Liabilities86.7 M $+126.3%

Total Equity941.5 M $-7.0%

Cash & ST Investments956.4 M $-5.7%

Total Debt21.6 M $-4.6%

Net Debt-30.3 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
JANX	17.01	2.3%	8.31	91.6%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
JANX	17.01	2.3%	8.31	91.6%
KURA	6.15	22.5%	1.90	16.5%
DSGN	22.28	1.3%	3.19	94.6%
ABUS	54.26	0.2%	-0.59	93.9%
LXRX	18.79	28.4%	6.48	75.5%
PHAT	2.21	-49.4%	0.16	-110.4%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-77.5 M $—

Capital Expenditures945 K $+77.3%

Free Cash Flow-78.5 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
JANX	-358.8%	-363.2%	4.4%	67.7%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
JANX	-358.8%	-363.2%	4.4%	67.7%
KURA	-108.9%	-117.9%	9.0%	26.5%
DSGN	—	—	—	77.5%
ABUS	-17.9%	-17.9%	4.2%	-21.4%
LXRX	-55.7%	-55.7%	0.0%	148.7%
PHAT	-47.6%	-47.5%	0.1%	62.0%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on JANX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.